Estrella Immunopharma's Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Estrella Immunopharma (ESLA).
Over the past two years, Estrella Immunopharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
EB103. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
EB103 FDA Regulatory Timeline and Events
EB103 is a drug developed by Estrella Immunopharma for the following indication: ARTEMIS® T-Cell Therapy.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- EB103
- Announced Date:
- February 9, 2026
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research)..
AI Summary
Estrella Immunopharma presented positive Phase I results from the STARLIGHT-1 study at the 2026 ASTCT & CIBMTR Tandem Meetings. The trial evaluates EB103, a CD19-targeted ARTEMIS T‑cell therapy for aggressive B‑cell non‑Hodgkin lymphoma. In the dose escalation portion, EB103 achieved a 100% complete response rate in the high‑dose cohort at Month 1, and all patients who reached complete response remained in that state at the data cutoff. Median duration of complete response has not yet been reached, with current durations ranging from 3 to 18 months. The data also included a complete responder with primary central nervous system lymphoma, a highly aggressive subtype.
Nine patients are reported so far, most high‑risk and ineligible for existing commercial CD19 products. No treatment‑related serious adverse events have been observed to date. Investigators described the responses and manageable toxicity as encouraging, supporting further development of EB103 as a potentially safer, more durable option for a broader group of B‑cell NHL patients.
Read Announcement- Drug:
- EB103
- Announced Date:
- February 3, 2026
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).
AI Summary
Estrella Immunopharma announced that results from its STARLIGHT-1 Phase I study will be presented orally at the 2026 ASTCT & CIBMTR Tandem Meetings. The company said the presentation is a late-breaking oral session and will showcase clinical findings from the ongoing study.
The STARLIGHT-1 study evaluates EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). The upcoming talk will highlight the clinical data gathered so far for EB103 in this patient group, giving attendees an early look at the study’s outcomes and the therapy’s performance in a challenging form of lymphoma.
Estrella is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS® T-cell therapies for cancer and autoimmune diseases. For more information, visit the company website.
Read Announcement- Drug:
- EB103
- Announced Date:
- December 4, 2025
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc. announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial.
AI Summary
An independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial and recommended moving the study into Phase II at the Recommended Phase II Dose (RP2D). The DSMB found a favorable safety profile with no treatment-related serious adverse events reported among the nine Phase I patients.
Most patients in the dose escalation were high-risk, including one with central nervous system (CNS) lymphoma. In the high-dose cohort, all evaluable patients achieved a complete response (100%) at Month 1, indicating promising early efficacy alongside the strong safety signal.
The expansion Phase II will further evaluate safety and preliminary efficacy of EB103, Estrella’s CD19-redirected ARTEMIS® T-cell therapy, in relapsed/refractory B-cell non-Hodgkin’s lymphoma. These Phase I results support EB103’s potential to reach higher-risk patients previously ineligible for current CD19 therapies, pending further study.
Read Announcement- Drug:
- EB103
- Announced Date:
- November 3, 2025
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphomas (NHL).
AI Summary
Estrella Immunopharma, Inc. announced the successful completion of the second dose cohort in the Phase I part of its STARLIGHT-1 Phase I/II trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy for advanced B-cell non-Hodgkin’s lymphoma. All evaluable patients in this cohort achieved a complete response at Month 1, marking a 100% response rate.
These patients were high-risk and not eligible for existing CD19 products, including one with central nervous system lymphoma. No treatment-related serious adverse events were reported, highlighting EB103’s favorable safety profile. According to CEO Cheng Liu, PhD, the milestone highlights EB103’s potential as a safe, effective option for cancer patients with limited choices.
The cohort included relapsed or refractory patients who had failed multiple therapies. A Data and Safety Monitoring Board will now review the data to set the recommended Phase II dose before moving into the dose expansion phase of STARLIGHT-1.
Read Announcement- Drug:
- EB103
- Announced Date:
- June 5, 2025
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
AI Summary
Estrella Immunopharma, Inc. has expanded its STARLIGHT-1 Phase I/II clinical trial by activating a second clinical site at Baylor Research Institute in Dallas, Texas. This site will enroll patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) for a study of EB103, a CD19-Redirected ARTEMIS® T-cell therapy. The trial is designed as an open-label, dose escalation study to assess the safety of EB103 and determine the recommended Phase II dose.
By partnering with a well-respected institution like Baylor Research Institute, Estrella aims to broaden the trial’s reach and accelerate patient access to this new treatment option. The company views this expansion as a key step to developing safer and more effective therapies for patients with advanced NHL, thereby furthering its mission to harness the power of the immune system against cancer.
Read Announcement- Drug:
- EB103
- Announced Date:
- September 27, 2024
- Indication:
- ARTEMIS® T-Cell Therapy
Announcement
Estrella Immunopharma, Inc announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial has achieved a complete response (CR) one month after receiving an infusion of EB103 CD19- Redirected ARTEMIS® T Cells.
AI Summary
Estrella Immunopharma, Inc. announced that the first patient enrolled in its STARLIGHT-1 Phase I/II clinical trial achieved a complete response (CR) just one month after receiving an infusion of EB103 CD19-Redirected ARTEMIS® T Cells. This result means that there are now no detectable signs of disease following the treatment. The patient, diagnosed with follicular lymphoma grade 3A and high-risk symptoms, had relapsed after three previous treatments and was considered high-risk, facing a greater chance of severe side effects from traditional CAR-T therapies. Importantly, the patient experienced no treatment-related serious adverse events such as cytokine release syndrome or neurotoxicity. Estrella is encouraged by these early safety and efficacy results and is focused on developing ARTEMIS® T-cell therapies that could improve on the effectiveness and safety of existing treatments, potentially making these therapies more accessible in a variety of hospital settings.
Read Announcement
Estrella Immunopharma FDA Events - Frequently Asked Questions
As of now, Estrella Immunopharma (ESLA) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Estrella Immunopharma (ESLA) has reported FDA regulatory activity for EB103.
The most recent FDA-related event for Estrella Immunopharma occurred on February 9, 2026, involving EB103. The update was categorized as "Positive Results," with the company reporting: "Estrella Immunopharma, Inc presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research).."
Currently, Estrella Immunopharma has one therapy (EB103) targeting the following condition: ARTEMIS® T-Cell Therapy.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:ESLA last updated on 2/9/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
